The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | bb2121: bringing CAR T-cells into the multiple myeloma world
Idecabtagene vicleucel (formerly bb2121) is a chimeric antigen receptor (CAR) T-cell product targeting the B-cell maturation antigen (BCMA), which is universally expressed on plasma cells (myemola cells). At the European Hematology Association (EHA) 2017 meeting, Yi Lin, MD, PhD from the Mayo Clinic, Rochester, MN, presented the latest data from a multicenter study in patients with relapsed/refractory multiple myeloma.
